RO
ROP.SW Roche Holding AG
- Market cap
- CHF 320B
- P/E
- 26.2x
- P/B
- 9.72x
- ROE
- 84.1%
- Dividend yield
- 2.62%
- Fundamental score
- 3.2/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ROP.SW undervalued?
Graham numberThe Graham number of Roche Holding AG cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Roche Holding AG fundamental analysis
15 of 22 checks passedROE 2/2
High return on equity (84.1%), above 20%.
ROA 1/1
Return on assets (28.0%) is above the industry median (15.1%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (55.4%) is above the 5-year average (-0.6% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (55.4%) is above the industry median (41.6%).
Revenue Growth 0/2
Revenue shrank 2.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (97.3%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 14.7x against interest expense, well covered.
PE vs Market 0/1
PE (26.2x) is above the market median (21.2x).
PE vs Industry 1/1
PE (26.2x) is below the industry median (29.3x).
PBV 0/1
Price to book (9.7x) is above the industry median (8.9x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 254.7, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (2.6%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 11 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 65.1%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Roche Holding AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various dise…
Full company profileRoche Holding AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Roche Holding AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 52.6B | 55.7B | 59.5B | 63.8B | 58.3B | 62.8B | 65.8B | 60.4B | 62.4B | 61.5B | 121B |
| Gross Profit | 37.6B | 39.9B | 43.0B | 46.4B | 42.0B | 43.1B | 47.9B | 44.1B | 46.1B | 45.2B | 89.5B |
| Operating Income | 16.8B | 17.3B | 18.9B | 21.0B | 17.7B | 18.2B | 17.5B | 15.4B | 13.4B | 19.3B | 37.8B |
| EBITDA | 17.7B | 16.7B | 18.3B | 21.5B | 23.0B | 22.2B | 20.8B | 18.4B | 16.6B | 22.7B | 44.6B |
| Net Income | 9.58B | 8.63B | 10.5B | 13.5B | 14.3B | 13.9B | 12.4B | 11.5B | 8.28B | 12.9B | 27.5B |
| EPS | 11 | 10 | 12 | 16 | 17 | 16 | 16 | 14 | 10 | 16 | 34 |
| Balance Sheet | |||||||||||
| Total Assets | 76.8B | 76.7B | 78.5B | 83.1B | 86.1B | 92.3B | 88.2B | 90.5B | 102B | 101B | 98.2B |
| Total Liabilities | 50.4B | 47.7B | 48.2B | 47.2B | 46.4B | 64.0B | 56.1B | 57.2B | 65.6B | 62.8B | 61.5B |
| Shareholders' Equity | 23.9B | 26.4B | 27.6B | 32.7B | 36.3B | 24.5B | 28.0B | 29.3B | 31.8B | 33.8B | 32.7B |
| Cash & Short-term Investments | 9.13B | 12.0B | 13.1B | 11.9B | 12.3B | 13.0B | 9.77B | 10.5B | 17.3B | 15.5B | 9.73B |
| Total Debt | 22.4B | 19.0B | 18.8B | 15.6B | 15.4B | 32.6B | 26.5B | 30.8B | 36.4B | 33.2B | 31.8B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 15.0B | 18.0B | 20.0B | 22.4B | 18.2B | 20.6B | 17.9B | 16.1B | 20.1B | 17.8B | 28.7B |
| Capital Expenditure | 4.14B | 3.51B | 4.04B | 3.50B | 6.69B | 4.55B | 4.55B | 4.65B | 5.01B | 3.75B | 6.28B |
| Free Cash Flow | 10.9B | 14.5B | 15.9B | 18.9B | 11.5B | 16.0B | 13.3B | 11.4B | 15.1B | 14.1B | 22.4B |
| Ratios | |||||||||||
| ROE | 40.0% | 32.7% | 38.0% | 41.2% | 39.3% | 56.9% | 44.4% | 39.2% | 26.1% | 38.1% | 84.1% |
| ROA | 12.5% | 11.3% | 13.4% | 16.2% | 16.6% | 15.1% | 14.1% | 12.7% | 8.1% | 12.8% | 28.0% |
| Net Profit Margin | 18.2% | 15.5% | 17.6% | 21.2% | 24.5% | 22.2% | 18.9% | 19.0% | 13.3% | 20.9% | 22.6% |
| Debt to Equity | 0.93x | 0.72x | 0.68x | 0.48x | 0.42x | 1.33x | 0.95x | 1.05x | 1.14x | 0.98x | 0.97x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Roche Holding AG dividends
- Dividend yield
- 2.62%
- Forward dividend
- 9.80 CHF
- Payout ratio
- 65.1%
- Ex-dividend date
- Mar 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CHF 8.39B | 10 | 65.1% |
| 2024 | CHF 7.65B | 9.54 | 92.4% |
| 2023 | CHF 7.59B | 9.44 | 66.0% |
| 2022 | CHF 7.45B | 9.31 | 59.9% |
| 2021 | CHF 7.77B | 9.04 | 55.8% |
| 2020 | CHF 7.70B | 8.90 | 53.9% |
| 2019 | CHF 7.45B | 8.62 | 55.2% |
| 2018 | CHF 7.25B | 8.43 | 69.1% |
| 2017 | CHF 7.14B | 8.30 | 82.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 100:1 on May 4, 2001.
Who owns Roche Holding AG
- Insiders 0.00%
- Institutions 44.76%
- Public & others 55.24%
- Shares outstanding 690M
- Free float 724M
Roche Holding AG company profile
- Company name
- Roche Holding AG
- Ticker
- ROP.SW
- ISIN
- CH1499059983
- Exchange
- SIX Swiss Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 103,249
- Fiscal year end
- December
- Address
- Grenzacherstrasse 124, Basel, Switzerland, 4070
- Phone
- 41 61 688 88 80
- Website
- roche.com
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Roche Holding AG management
10- Dr. Severin Schwan Ph.D.Executive Chairman · born 1967
- Dr. Thomas SchineckerGroup Chief Executive Officer · born 1975
- Dr. Alan HippeChief Financial Officer · born 1967
- Ms. Wafaa MamilliChief Digital & Technology Officer · born 1967
- Dr. Bruno EschliHead of Investor Relations
- Ms. Claudia BockstiegelGeneral Counsel · born 1964
- Dr. Nina Schwab-HautzingerHead of Group Communications · born 1975
- Ms. Maria Cristina A. WilburChief People Officer · born 1967
- Dr. Nicolas DunantHead of Group Media Relations
- Mr. Boris L. ZaitraHead of Corporate Business Development · born 1972